8月15日，医美与消费医疗服务平台新氧科技公布第二季度财报。财报显示，第二季度，新氧总营收为3.787亿元，2024年同期为4.074亿元，同比下滑7%； 净亏损为3600万元，2024年同期为净利润1890万元；在非美国通用会计准则（Non-GAAP）下，新氧经调整后净亏损为3050万元，2024年同期为净利润2220 万元。 | | For the Inree M | | | --- | --- | --- | | | June 30, | June | | | 2024 | 207 | | | RMB | RM | | Revenues: | | | | Aesthetic treatment services | 27,444 | 144 | | Information and reservation services | 209,734 | 135 | | Sales of medical products and maintenance services | 105,808 | 76 | | Other services | 64,394 | 23 | | Total revenues | 407 ...

智通财经APP获悉，周三，新氧(SY.US)股价走高，截至发稿，该股涨超7.7%，报5.181美元。该公司将 于08月15日盘前发布最新财报。 ...

新华社伦敦8月7日电 英国卫生安全局7日发布公报警告说，英国已确诊多起美容手术后发生的肉毒 杆菌中毒病例。该机构提醒公众接受涉及肉毒杆菌毒素的美容手术时要警惕相关风险。 肉毒杆菌毒素是肉毒杆菌产生的含有高分子蛋白的神经毒素，具有很强的神经毒性。该毒素通过麻 痹皮下神经，可在一段时间内消除皱纹或避免皱纹生成，因此广泛应用于医美领域。 英国卫生安全局已向全英临床医生发布建议，确保他们密切关注近期接受过美容手术的人群是否出 现肉毒杆菌中毒症状，以对患者提供治疗。该机构建议公众在寻求美容治疗时采取预防措施，包括检查 所用产品是否获得许可，以及不要从网上购买产品自行使用。 英国卫生安全局医学微生物学顾问高丽·戈德博尔表示，与美容手术相关的肉毒杆菌中毒虽然罕 见，但可能非常严重，症状可能需要长达4周才会出现。 公报说，今年6月4日至8月6日期间，已报告41例临床确诊的医源性肉毒杆菌中毒病例，症状包括吞 咽困难、言语不清、呼吸困难等。尽管调查仍在进行，但现有证据表明，中毒事件与使用未经许可的肉 毒杆菌毒素产品有关，一些病例与手术操作有关。 ...

Core Viewpoint - The article highlights the growing popularity of water light needles among young consumers due to their "minimally invasive beauty" characteristics, while also revealing regulatory violations in the medical aesthetics industry regarding the use of medical devices [1] Group 1: Industry Insights - Water light needles have become a preferred choice for many young individuals seeking cosmetic enhancements [1] - Some legitimate medical aesthetic institutions are found to be illegally using Class II medical products for injections, which raises concerns about consumer safety [1] Group 2: Regulatory Issues - According to the National Medical Products Administration's classification rules, injections into the skin must utilize Class III medical products [1] - A specific case was reported at Guangdong Hanfei Plastic Surgery Hospital, where Class II product "Sili 516 Energy Essence" was used for injections, violating regulations [1] - The hospital's management attempted to confuse the distinction between Class II and Class III products, misleading consumers about the safety of their procedures [1]

Group 1 - The article highlights the increasing popularity of water light injections among young people due to their "minimally invasive beauty" characteristics, but also points out the illegal practices in the industry [1][3] - Several legitimate medical beauty institutions are found to be violating regulations by using Class II medical devices for injections, which are not approved for such use [5][13] - The investigation reveals that some beauty clinics and unauthorized beauty shops are openly providing injection services without proper medical qualifications [32][41] Group 2 - The Guangdong Hanfei Plastic Surgery Hospital misleads consumers about the classification of their water light products, claiming they are safe for injection despite being Class II devices [7][15] - The Ji Yan Xi Medical Beauty Clinic is also implicated in illegally injecting Class II products, with the physician providing vague responses to inquiries about compliance [22][30] - A beauty shop named Yujianmei Technology is found to be operating without medical qualifications, using smuggled products for injections [34][39] Group 3 - The article discusses the presence of unregulated and illegal products in the market, including foreign water light injections without proper labeling and approval [41][47] - The investigation uncovers that platforms like Xiaohongshu are being used by drug dealers and unauthorized personnel to connect with customers for illegal injection services [51][57] - The report emphasizes the dangers of low-priced products being marketed as water light injections, which are actually intended for other medical uses [67][68]

Core Viewpoint - The report highlights the misuse of medical products in the cosmetic industry, specifically the injection of products not approved for facial use, raising concerns about safety and regulatory compliance [1]. Group 1: Product Misuse - A medical beauty store in Lianyungang was found to be using a product intended for abdominal surgery, specifically a sodium hyaluronate gel, for facial injections, which is not its approved application [1]. - The store required customers to purchase an additional product under the pretense that the initially chosen product was insufficient for full facial treatment, despite the second product also being inappropriate for facial use [1]. Group 2: Regulatory Concerns - The report indicates that similar products, which are classified as Class III medical devices, are being marketed inappropriately within the medical beauty sector, leading to potential health risks for consumers [1]. - The use of these products, which are meant to prevent postoperative adhesions in the abdominal cavity, raises significant questions about the enforcement of regulations in the cosmetic industry [1].

Group 1 - The article highlights the illegal practices in the beauty industry, particularly regarding the use of Class II medical devices for injection, which are not approved for such procedures [1][4][24] - Several medical institutions, including Guangdong Hanfei Plastic Surgery Hospital and Jiyuanxi Medical Beauty Clinic, mislead consumers about the safety and classification of their products, promoting Class II devices as safe for injection [6][16][26] - The investigation reveals that unauthorized beauty salons and studios are openly providing injection services without proper medical qualifications, using smuggled and unapproved products [29][33][49] Group 2 - The report details specific instances where medical professionals and institutions provided injections of products that are not legally permitted for such use, including the "Silk 516" and "Lizhulan" products [7][18][24] - The article also discusses the role of social media platforms like Xiaohongshu in facilitating the promotion and sale of these illegal beauty products, allowing unlicensed practitioners to connect with customers [44][56] - The investigation uncovers a broader issue of counterfeit and unregulated beauty products flooding the market, posing significant risks to consumer safety [38][41][47]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $44 million, a decline of 13.7% from the prior year quarter, with adjusted EBITDA at $5.8 million, reflecting a margin of 13.3% compared to 13.5% in Q2 2024 [7][18][20] - Same store revenue declined approximately 22% year-over-year, although it improved marginally from Q1 2025 [8][18] - Average revenue per case was approximately $12,975, consistent with the previous year [18] Business Line Data and Key Metrics Changes - Cases declined by 14.1% to 3,392, primarily due to a challenging market environment [18] - The percentage of patients using financing for procedures increased to 50%, up from 44% in Q1 2025 [19] - Customer acquisition cost decreased to $2,905 per case from $3,325 in the prior year quarter, marking the first quarter-over-quarter decline since going public [20] Market Data and Key Metrics Changes - The company experienced strong consumer interest, with record levels of lead growth and increased consultation volume [7][11] - The macroeconomic environment remains challenging, impacting consumer spending and leading to hesitancy in purchasing decisions [28][46] Company Strategy and Development Direction - The company is focused on five business priorities: enhancing marketing strategies, optimizing sales, introducing new services, improving customer experience, and investing in technology [10][11][12][14] - A pilot for a new skin tightening procedure was launched in Q2 2025, with plans to expand it further [13][31] - The company aims to stabilize sales and return to growth, with no planned new center openings for 2025 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategy to stabilize sales and improve profitability despite the challenging operating environment [7][15] - The company reiterated its annual outlook, expecting revenue between $160 million and $170 million and adjusted EBITDA between $16 million and $18 million for fiscal 2025 [23] Other Important Information - The CFO announced plans to retire later in the year, with a search underway for a replacement [5] - The company repaid $16 million in debt during the quarter, improving its financial position [21][22] Q&A Session Summary Question: Guidance implies revenues that are flattish in the second half, what are the drivers for the acceleration? - Management noted that while consumer uncertainty persists, record high leads and consultation growth are expected to stabilize revenue and improve EBITDA margins in the second half [28][29] Question: Update on the skin tightening offering and its impact on revenue? - Management confirmed that there are no standalone expectations for skin tightening in guidance, but strong interest has been observed [31][32] Question: Performance of the new centers opened in 2024? - The new centers are performing in line with expectations, though lower than historical averages due to consumer pressures [36][37] Question: Any seasonality considerations for Q3? - Management indicated typical softening in Q3, with expectations for improvement in Q4 as cost initiatives take effect [38][39] Question: Update on the London facility's performance? - The London facility has shown improvement but remains cash flow negative, with management focused on enhancing results [41] Question: Insights on consumer sentiment and market dynamics? - Management noted a choppiness in consumer behavior, with consumers hesitant to make purchases, but believes the company is well-positioned compared to competitors [46]

Core Viewpoint - The article highlights the booming trend of "medical beauty + tourism" among young students in China, particularly after the college entrance examination, indicating a significant increase in demand for cosmetic procedures during the summer months [3][10][11]. Group 1: Market Trends - The summer period post-exams sees a surge in medical beauty procedures, with reports indicating a 10% to 30% increase in student patients at certain hospitals [5][8]. - Popular procedures among students include double eyelid surgery, rhinoplasty, and facial contouring, with a reported 30% increase in related business during the summer [7][10]. - The trend of students traveling to major cities or abroad for cosmetic procedures is growing, with a notable flow from second and third-tier cities to first-tier cities and international destinations like South Korea and Japan [8][10]. Group 2: Economic Impact - The report from Deloitte indicates that 31% of middle to high-income individuals plan to seek cosmetic procedures abroad in 2024, translating to over 9 million potential outbound medical beauty seekers based on current estimates [10]. - Chengdu is positioning itself as an "international medical beauty capital," with plans to achieve a revenue target of 100 billion yuan by 2025 [16]. Group 3: Consumer Behavior - Young consumers are increasingly calculating the cost-benefit ratio of beauty procedures, often opting for international options due to lower prices and perceived higher quality [9][14]. - Social media plays a significant role in promoting this trend, with platforms like Xiaohongshu and Douyin generating substantial discussions and views on beauty transformations and travel experiences [11]. Group 4: Service and Infrastructure - South Korea offers comprehensive services for medical tourists, including medical visas and bilingual support, enhancing the appeal for Chinese students seeking cosmetic procedures [15]. - Domestic cities are also exploring innovative models that combine tourism and medical beauty, with initiatives to develop unique beauty tourism routes [16]. Group 5: Risks and Challenges - Despite the growing trend, there are significant risks associated with low-cost procedures, including the potential for infections and financial pitfalls from "beauty loans" [18][19]. - Language barriers and lack of regulatory oversight for local guides can lead to miscommunication and unsafe practices in foreign medical settings [20].

Group 1 - The core viewpoint of the news is that the Chengdu metropolitan area has achieved significant economic growth in the first half of the year, with a total GDP of 15,171.78 billion yuan, driven primarily by Chengdu's dominance in the region [1][2] - Chengdu's GDP accounts for 79.8% of the total GDP of the metropolitan area, highlighting its central role in the economic landscape [1] - The metropolitan area has identified nine key industrial chains, with a total output value exceeding one trillion yuan, focusing on sectors such as new displays, rail transit, aerospace equipment, new energy vehicles, green food, and medical beauty services [1] Group 2 - The production output of key industrial products has seen robust growth, with Chengdu's new energy vehicles, smartwatches, and lithium-ion batteries increasing by 352.2%, 119.2%, and 45.8% respectively [1] - The third industry in Chengdu, which includes services, has shown a significant increase, with a value of 8,654.2 billion yuan, representing 71.5% of the regional GDP [2] - Deyang continues to leverage its strengths in equipment manufacturing, with a reported revenue of 1,799.0 billion yuan from large-scale industrial enterprises, reflecting a year-on-year growth of 10.8% [2]